Comparing Vasopressin and Hydrocortisone as Adjunctive Measures in Septic Shock

Area of Science:

• Critical Care Medicine
• Pharmacology
• Clinical Trials

Background:

• Norepinephrine is the primary agent for hemodynamic support in septic shock.
• The optimal timing and sequence of vasopressin and hydrocortisone as adjunctive therapies remain debated.
• Emerging evidence suggests early hydrocortisone may decrease mortality.

Purpose of the Study:

• To compare the effectiveness and safety of vasopressin versus hydrocortisone as adjuncts to norepinephrine in septic shock.
• To assess the impact of initial adjunctive agent choice on patient outcomes.

Main Methods:

• Multicenter, retrospective, observational study of adult septic shock patients in the ICU.
• Two cohorts: initial adjunctive therapy with vasopressin or hydrocortisone post-norepinephrine.
• Primary outcome: in-hospital mortality; Secondary outcomes: ICU/hospital length of stay, vasopressor discontinuation, renal replacement therapy, safety.

Main Results:

• Hydrocortisone group (n=193) showed lower in-hospital mortality (37.3%) than vasopressin group (n=435, 53.3%).
• Adjusted hazard ratio for mortality with hydrocortisone was 1.80 (95% CI 1.19-2.74, P=0.006).
• Hydrocortisone was associated with shorter hospital LOS and less RRT initiation.

Conclusions:

• Hydrocortisone as an initial adjunct to norepinephrine in septic shock is associated with reduced in-hospital mortality compared to vasopressin.
• Early initiation of hydrocortisone may enhance clinical outcomes in septic shock.
• Consider early hydrocortisone in patients with escalating norepinephrine requirements.